Bausch + Lomb (BLCO) Competitors $13.88 +0.12 (+0.87%) As of 01:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. SNN, SOLV, PEN, STVN, GKOS, IRTC, NARI, TMDX, SLNO, and INSPShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos iRhythm Technologies Inari Medical TransMedics Group Soleno Therapeutics Inspire Medical Systems Bausch + Lomb (NYSE:BLCO) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the media favor BLCO or SNN? In the previous week, Bausch + Lomb had 12 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 13 mentions for Bausch + Lomb and 1 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 1.43 beat Bausch + Lomb's score of 0.22 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, BLCO or SNN? Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch + Lomb$4.79B1.02-$317M-$1.03-13.48Smith & Nephew SNATS$5.81B2.28$412M$2.1614.02 Do analysts prefer BLCO or SNN? Bausch + Lomb currently has a consensus target price of $15.54, suggesting a potential upside of 11.97%. Smith & Nephew SNATS has a consensus target price of $28.00, suggesting a potential downside of 7.53%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, research analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch + Lomb 1 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.23Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders have more ownership in BLCO or SNN? 11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BLCO or SNN more profitable? Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -7.50%. Bausch + Lomb's return on equity of 2.62% beat Smith & Nephew SNATS's return on equity.Company Net Margins Return on Equity Return on Assets Bausch + Lomb-7.50% 2.62% 1.28% Smith & Nephew SNATS N/A N/A N/A Which has more volatility & risk, BLCO or SNN? Bausch + Lomb has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. SummarySmith & Nephew SNATS beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$4.91B$7.31B$5.50B$20.64BDividend YieldN/A2.77%5.39%3.77%P/E Ratio-13.4827.9927.4228.03Price / Sales1.0232.28398.5038.91Price / Cash7.1821.4136.1321.91Price / Book0.756.678.014.60Net Income-$317M$233.06M$3.16B$984.95M7 Day Performance15.01%2.08%2.08%2.95%1 Month Performance20.64%4.79%4.38%5.53%1 Year Performance-5.32%35.43%35.81%14.66% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb3.3757 of 5 stars$13.88+0.9%$15.54+12.0%-6.2%$4.91B$4.79B-13.4813,500SNNSmith & Nephew SNATS3.7776 of 5 stars$29.17+1.2%$28.00-4.0%+22.2%$12.77B$5.81B13.5017,349Positive NewsSOLVSolventum0.9013 of 5 stars$73.21-0.5%$80.29+9.7%+51.6%$12.67B$8.31B33.8922,000Positive NewsAnalyst UpgradePENPenumbra4.7339 of 5 stars$254.41-1.0%$302.40+18.9%+41.8%$9.85B$1.19B240.014,500Positive NewsSTVNStevanato Group0.9763 of 5 stars€23.62+1.4%N/A+36.2%€7.15B€1.19B46.315,521Positive NewsAnalyst ForecastGap DownGKOSGlaukos4.3607 of 5 stars$96.80-3.3%$134.67+39.1%-12.8%$5.53B$383.48M-40.84780IRTCiRhythm Technologies1.1904 of 5 stars$150.95+3.6%$138.60-8.2%+44.8%$4.82B$591.84M-48.072,000Positive NewsInsider TradeNARIInari Medical0.4681 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800TMDXTransMedics Group1.6056 of 5 stars$127.53+3.2%$127.33-0.2%-14.3%$4.31B$441.54M93.77210Positive NewsSLNOSoleno Therapeutics4.2152 of 5 stars$81.42+1.8%$107.10+31.5%+117.0%$4.10BN/A-17.6230INSPInspire Medical Systems4.8493 of 5 stars$129.88-0.8%$211.91+63.2%-2.7%$3.83B$840.11M59.851,246Positive News Related Companies and Tools Related Companies Smith & Nephew SNATS Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors Glaukos Competitors iRhythm Technologies Competitors Inari Medical Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Inspire Medical Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLCO Stock Alerts